Off label Administration of Buprenorphine in the Treatment of Major Depression

Ahmadi, Jamshid

doi:10.4172/2167-1044.1000263

Cited by 2 publications

(2 citation statements)

References 10 publications

(10 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, in the rat model, administration of κ-opioid receptor agonists can induce depressive conditions (9). Previous studies indicated the effects of buprenorphine in the reduction of suicidality and depression (40)(41)(42).…”

Section: Discussionmentioning

confidence: 99%

Fast Effect of Buprenorphine on Opioid-dependent Patients with Suicidal Ideation: A Novel Approach

Ahmadi

Jahromi

2018

Int J High Risk Behav Addict

Self Cite

View full text Add to dashboard Cite

Background: Buprenorphine is usually administered to manage opioid use disorder and pain syndromes. It could be a proper treatment option for suicidality, resistant depression, self-destructive behavior, and anxiety. Buprenorphine has a considerable abuse potential that confines its administration in patients committing suicide with a background of substance abuse. Objectives: The current study aimed at clarifying the influence of different doses of buprenorphine on opioid-dependent patients committing suicide over a 2-day period in a randomized, clinical trial (RCT). Methods: Patients were randomly assigned into 3 groups. Twenty-three suicidal male patients who met the DSM-5 (diagnostic and statistical manual of mental disorders) criteria for opioid dependence and sought treatment were recruited. Patients randomly received 32, 64, or 96 mg of buprenorphine as a single high-dose only and were hospitalized in a psychiatric inpatient ward. Out of the 23 patients, 9 (39.2%), 8 (34.8%), and 6 (26%) received 32, 64, and 96 mg of buprenorphine, respectively. Psychometric assessment was performed using the Beck scale for suicidal ideation (BSSI) and interview. All patients completed the 2-day treatment period. The results indicated a significant decrease in BSSI scores in each of the 3 groups (P < 0.05), but there was no difference in the outcome between the groups (P = 0.30). Conclusions:The current study results indicated that a single high-dose of buprenorphine could provide a speedy and safe means to treat suicidality in opioid-dependent patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Fast Effect of Buprenorphine on Opioid-dependent Patients with Suicidal Ideation: A Novel Approach

Ahmadi

Jahromi

2018

Int J High Risk Behav Addict

Self Cite

View full text Add to dashboard Cite

show abstract

“…Besides, buprenorphine is a partial agonist of mu-opioid receptor, so it decreases the level of suicidal desire, depression, dysphoria, anxiety, pain, and opioid withdrawal symptoms. In addition, buprenorphine is a strong kappa receptor antagonist, so it reduces suicidal thoughts, and depression [15][16][17][18][19][20][21][22][23][24][25][26][27][28][29].…”

Section: Discussionmentioning

confidence: 99%

“Efficacy of Buprenorphine in the Treatment of Suicide”

Ahmadi,

2018

GJARM

View full text Add to dashboard Cite

Background: Buprenorphine is currently used for the treatment of opioid use disorder and pain disorder. It could be an effective alternative option for the treatment of anxiety symptoms, depressive symptoms, self-destructive actions and suicidal ideations. However, it has a major potential for abuse and diversion that limits its application in these disorders. Objective: To explain the efficacy of buprenorphine in the treatment of Suicidal ideations. Conclusion: Buprenorphine can be an effective alternative option for the treatment of suicidal ideation.

show abstract

Off label Administration of Buprenorphine in the Treatment of Major Depression

Cited by 2 publications

References 10 publications

Fast Effect of Buprenorphine on Opioid-dependent Patients with Suicidal Ideation: A Novel Approach

Fast Effect of Buprenorphine on Opioid-dependent Patients with Suicidal Ideation: A Novel Approach

“Efficacy of Buprenorphine in the Treatment of Suicide”

Contact Info

Product

Resources

About